1,5-dibenzyl-1,5-dimethyl-biguanide | 102956-47-8

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 1,5-dibenzyl-1,5-dimethyl-biguanide
• 英文别名: 1,5-Dibenzyl-1,5-dimethyl-biguanid；1-benzyl-2-(N-benzyl-N-methylcarbamimidoyl)-1-methylguanidine
• CAS: 102956-47-8
• 化学式: C₁₈H₂₃N₅
• 分子量: 309.414
• InChiKey: HEFOFWUEAIMWMX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  23
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  68.7
• 氢给体数：
  2
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  N-甲基苄基胺盐酸盐 在 正丁醇 作用下， 生成 1,5-dibenzyl-1,5-dimethyl-biguanide
  参考文献：
  名称：

  Hypoglycemic Agents. IV.^1—3 N¹,N⁵-Alkyl- and Aralkylbiguanides

  摘要：

  DOI：

  10.1021/ja01526a047

文献信息

• Biguanide Derivative, A Preparation Method Thereof And A Pharmaceutical Composition Containing The Biguanide Derivative As An Active Ingredient
  申请人：Kim Sung Wuk

  公开号：US20120283299A1

  公开（公告）日：2012-11-08

  A biguanide derivative compound with N1-N5 substitution, which is represented by Formula 1, or a pharmaceutically acceptable salt thereof, a method of preparing the same, and a pharmaceutical composition containing the same as an active ingredient are provided. The biguanide derivative may exhibit excellent effect on activation of AMPKα and inhibition of cancer cell proliferation in a low dose, compared to conventional drugs, and thus, may be useful to treat diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, fatty liver, coronary artery disease, osteoporosis, polycystic ovarian syndrome, metabolic syndrome, cancer, etc.

  提供一种具有N1-N5取代的biguanide衍生物化合物，其由Formula 1表示，或其药学上可接受的盐，以及制备该化合物的方法，以及含有该化合物作为活性成分的药物组合物。与传统药物相比，这种biguanide衍生物可能在低剂量下对AMPKα的激活和对癌细胞增殖的抑制表现出出色的效果，因此可能有助于治疗糖尿病、肥胖、高脂血症、高胆固醇血症、脂肪肝、冠心病、骨质疏松症、多囊卵巢综合征、代谢综合征、癌症等疾病。
• Biguanide derivative, a preparation method thereof, and a pharmaceutical composition containing the biguanide derivative as an active ingredient
  申请人：Immunomet Therapeutics Inc.

  公开号：US10376480B2

  公开（公告）日：2019-08-13

  A biguanide derivative compound with N1-N5 substitution, which is represented by Formula 1, or a pharmaceutically acceptable salt thereof, a method of preparing the same, and a pharmaceutical composition containing the same as an active ingredient are provided. The biguanide derivative may exhibit excellent effect on activation of AMPKα and inhibition of cancer cell proliferation in a low dose, compared to conventional drugs, and thus, may be useful to treat diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, fatty liver, coronary artery disease, osteoporosis, polycystic ovarian syndrome, metabolic syndrome, cancer, etc.

  本发明提供了一种由式 1 表示的具有 N1-N5 取代的双胍衍生物化合物或其药学上可接受的盐、其制备方法以及以其为活性成分的药物组合物。与传统药物相比，该双胍衍生物可在低剂量下表现出良好的激活 AMPKα 和抑制癌细胞增殖的效果，因此可用于治疗糖尿病、肥胖症、高脂血症、高胆固醇血症、脂肪肝、冠心病、骨质疏松症、多囊卵巢综合征、代谢综合征、癌症等。
• Biguanide Derivative, A Preparation Method Thereof, And A Pharmaceutical Composition Containing The Biguanide Derivative As An Active Ingredient
  申请人：IMMUNOMET THERAPEUTICS INC.

  公开号：US20160317478A1

  公开（公告）日：2016-11-03

  A biguanide derivative compound with N1-N5 substitution, which is represented by Formula 1, or a pharmaceutically acceptable salt thereof a method of preparing the same, and a pharmaceutical composition containing the same as an active ingredient are provided. The biguanide derivative may exhibit excellent effect on activation of AMPKα and inhibition of cancer cell proliferation in a low dose, compared to conventional drugs, and thus, may be useful to treat diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, fatty liver, coronary artery disease, osteoporosis, polycystic ovarian syndrome, metabolic syndrome, cancer, etc.
• US9416098B2
  申请人：——

  公开号：US9416098B2

  公开（公告）日：2016-08-16
• US9993446B2
  申请人：——

  公开号：US9993446B2

  公开（公告）日：2018-06-12